Claims for Patent: 8,952,064

Summary for Patent: 8,952,064

Title:	Pharmaceutical semi-solid composition of isotretinoin
Abstract:	An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle
Inventor(s):	Vanderbist; Francis (Beersel, BE), Servais; Cecile (Malonne, BE), Baudier; Philippe (Uccle, BE)
Assignee:	Galephar Pharmaceutical Research, Inc. (Humacao, PR)
Application Number:	13/525,857
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,952,064
Patent Claims:	1. An oral pharmaceutical composition in the form of a capsule, wherein the capsule is filled with a composition consisting essentially of a semisolid paste of isotretinoin in a mixture of oil and a glycerol macrogolglyceride of HLB of at least 10, said composition exhibiting a dissolution of at least 40% within 4 hours as measured using USP paddle apparatus at 150 rpm in an aqueous dissolution medium constituted by buffer of pH 7.5, sodium lauryl sulfate 2.5% and pancreatin 1 g/L at 37.degree. C. 2. The oral pharmaceutical composition of claim 1, wherein the composition exhibits an isotretinoin release rate of at least 60% within 4 hours. 3. The oral pharmaceutical composition of claim 1, wherein isotretinoin comprises between 1% to 25% w/w of the composition, the oil comprises between 20% to 80% w/w of the composition and the macrogolglyceride comprises between 5% to 70% w/w of the composition. 4. The oral pharmaceutical composition of claim 1, wherein the oil excipient is selected from the group consisting of vegetable oils, medium chain triglycerides, fatty acid esters, glycerol oleate and mixtures thereof. 5. The oral pharmaceutical composition of claim 1, wherein the glycerol macrogolglyceride excipient has a HLB value of at least 12. 6. The oral pharmaceutical composition of claim 1, wherein the glycerol macrogolglyceride excipient has a HLB value of at least 13. 7. The oral pharmaceutical composition of claim 1, wherein the composition is as semi-solid suspension. 8. The oral pharmaceutical composition of claim 1, which further comprises at least one surfactant. 9. The oral pharmaceutical composition of claim 8, wherein the surfactant is selected from the group consisting of sorbitan fatty acid esters, polysorbate compounds, polyoxyethylene sorbitan fatty acids esters, sodium lauryl sulphate compounds of lecithin, propylene glycol esters, fatty acid esters of propylene glycol, fatty acid esters of glycerol, and mixtures thereof. 10. The oral pharmaceutical composition of claim 8, wherein the surfactant comprises between 1% to 10% w/w of the composition. 11. The oral pharmaceutical composition of claim 1, which further comprises at least one disintegrant. 12. The oral pharmaceutical composition of claim 11, wherein the disintegrant is selected from the group consisting of crospovidone, sodium croscarmellose, and mixtures thereof.